New Study: An Inflammation Marker That Outperforms CRP in Heart Failure Survival Prediction

Inflammation and heart disease have been linked in research for decades. The JUPITER trial established that people with normal LDL cholesterol but elevated hs-CRP had meaningfully higher cardiovascular risk, and that reducing CRP with a statin lowered that risk even without moving cholesterol much. CRP became the standard inflammation marker in cardiology, and for good reason: it is inexpensive, widely available, and sensitive to even modest increases in systemic inflammatory activity.

But research rarely stands still. A study published in the Journal of Inflammation Research in September 2026 asked a pointed question: does hs-CRP give us the whole picture in heart failure, or does a newer marker do better? The answer surprised some cardiologists, and it has implications for anyone who thinks carefully about how inflammation is measured and what different measurements actually capture.

What the New Study Found

The research team analyzed data from 4,622 patients with acute heart failure enrolled in a nationwide Chinese prospective cohort. Participants were followed for a median of 4.61 years, during which the researchers tracked all-cause mortality, cardiovascular mortality, major adverse cardiovascular events, and hospitalizations for heart failure. Both NPAR and hs-CRP were measured at baseline, and the team used multivariable Cox regression to understand how each marker related to outcomes after accounting for age, sex, other comorbidities, and standard clinical variables (Chen et al., Journal of Inflammation Research, 2026).

The mortality gradient across NPAR quartiles was steep. Compared with patients in the lowest NPAR quartile, those in the highest quartile had a hazard ratio of 1.74 (95% confidence interval: 1.52 to 1.99) for all-cause mortality and 1.72 (95% CI: 1.46 to 2.03) for cardiovascular mortality. The dose-response pattern was consistent: each successive quartile carried higher risk, suggesting that NPAR is picking up a genuine, graded biological signal rather than noise.

Adding NPAR to the statistical model improved prediction beyond standard clinical variables. The concordance index for all-cause mortality rose from 0.693 to 0.701 when NPAR was added, and the continuous net reclassification improvement was 9.90%, meaning the model correctly reclassified roughly one in ten patients from the wrong risk category to the right one. For cardiovascular mortality, the improvement was similar. These are meaningful gains when individual markers are being stacked on top of already-comprehensive clinical models.

When the researchers directly compared NPAR and hs-CRP, NPAR came out ahead. Adding hs-CRP to the base model improved discrimination less than adding NPAR did. Combining both markers together did not further improve predictive performance beyond NPAR alone, suggesting the two markers share overlapping information and that NPAR captures what hs-CRP captures plus something additional. The researchers concluded that NPAR may be useful for risk assessment in acute heart failure and could serve as an alternative or complement to hs-CRP in clinical practice.

What NPAR Measures and Why It Might Have an Edge

To understand why NPAR might carry more information than CRP alone in heart failure, it helps to unpack what each value reflects. Neutrophils are the most abundant white blood cells and the immune system's first responders to tissue injury and infection. When the body is under chronic inflammatory stress, neutrophil counts and their proportion of total white cells tend to rise. A higher neutrophil percentage signals ongoing immune activation, cytokine output, and tissue-level inflammation that tracks closely with cardiovascular damage and hemodynamic instability in heart failure.

Albumin, the denominator in NPAR, tells a different but equally important story. Albumin is the main protein in the blood, synthesized by the liver, and its level reflects both nutritional status and the severity of systemic inflammation. The liver prioritizes the production of acute-phase inflammatory proteins like CRP over albumin when inflammation is high, so albumin falls as CRP rises. A low albumin level therefore signals two things at once: inadequate protein nutrition and a strong ongoing acute-phase response. In heart failure specifically, albumin also reflects the degree of organ congestion and hepatic dysfunction, both of which worsen prognosis.

NPAR combines these two signals into a single ratio, and the combination appears to capture more signal than either component alone. A high neutrophil percentage plus a low albumin, the combination that produces a high NPAR, means the immune system is in an aggressive active state while nutritional and protein reserves are depleted. This represents a particularly precarious biological situation in which the body is simultaneously fighting inflammation and losing the metabolic resources needed to sustain cardiac function and repair. CRP, by contrast, captures the acute-phase response but does not directly encode anything about nutritional depletion or the neutrophil-to-lymphocyte immune balance.

A systematic review and meta-analysis published in Cardiology in Review in July 2026 reinforced this picture. Pooling seven studies that together enrolled 11,543 patients with heart failure, researchers found that higher baseline NPAR was significantly associated with increased all-cause mortality with a pooled hazard ratio of 1.65 (95% CI: 1.44 to 1.90; p less than 0.001). The dose-response relationship was consistent across all seven studies, and the certainty of evidence was rated as moderate using standard grading criteria (Patel et al., Cardiology in Review, 2026). The meta-analysis authors described NPAR as a "zero-cost biomarker derived from routine admission laboratories" that "captures the inflammation-malnutrition axis," and noted it may be especially useful in resource-limited settings where comprehensive biomarker panels are unavailable.

CRP Still Matters: What NPAR Does Not Replace

It is easy to read a headline about a new marker outperforming CRP and conclude that CRP is no longer useful. That would be the wrong takeaway. The new study was conducted specifically in patients already hospitalized with acute heart failure, a population with very high and volatile inflammatory burden. In that narrow clinical context, NPAR added predictive value. But CRP has decades of evidence behind it across a much wider range of conditions and populations, and the two markers are asking slightly different questions.

hs-CRP is sensitive to low-grade chronic inflammation, the kind that exists at a simmer in otherwise healthy people. At levels below 1 mg/L, hs-CRP signals very low cardiovascular risk. Between 1 and 3 mg/L it signals intermediate risk. Above 3 mg/L, and especially above 10 mg/L, it signals elevated risk from chronic inflammation. For a generally healthy person trying to understand their baseline inflammatory state, hs-CRP is the right tool. NPAR, which is derived partly from white cell counts that fluctuate with short-term factors like recent infection, stress, or steroid use, is less stable as a general population screening marker.

A 2026 review in Nutrients examined how different markers behave specifically in heart failure and concluded that systemic inflammation is a key driver of heart failure progression across all ejection fraction subtypes, and that CRP and IL-6 remain important general-purpose inflammatory signals even as newer markers emerge (Mavroudis et al., Nutrients, 2026). The Mediterranean diet, the review noted, is associated with meaningful reductions in circulating CRP and IL-6, underscoring that lifestyle interventions that move CRP still matter even in the era of more precise clinical markers. The availability of a more powerful clinical predictor in a hospitalized population does not change the value of tracking CRP trends over time in everyday life.

The NPAR story is better understood as an illustration of a broader principle than as a direct challenge to CRP. That principle is that inflammation is multidimensional. CRP reflects one important dimension: the liver's output of acute-phase proteins in response to cytokine signaling. NPAR reflects two others: the balance of the innate immune response and the state of protein stores and nutritional capacity. Depending on the question being asked, different markers will be more or less informative.

Why the Inflammation-Malnutrition Axis Matters

The phrase "inflammation-malnutrition axis" that researchers use in the NPAR literature points to something fundamental about chronic disease biology. Inflammation and nutritional depletion are not just correlated by accident. The inflammatory response is metabolically expensive: mounting an immune defense requires energy, amino acids, and micronutrients. In acute illness, and in the sustained low-grade inflammation of chronic disease, the body repeatedly draws on these reserves. Over time, that sustained drain can deplete albumin, reduce lean mass, impair immune regulation, and create a feedback loop in which nutritional inadequacy itself worsens inflammatory tone.

This loop is particularly visible in heart failure, where multiple forces converge to worsen both nutrition and inflammation. Reduced cardiac output limits gut perfusion, impairing nutrient absorption. Elevated venous pressure causes gut edema, which disrupts the intestinal barrier and allows bacterial products to translocate into circulation, directly activating inflammatory pathways. Elevated cytokines suppress appetite and accelerate muscle breakdown. And many heart failure patients have co-existing conditions such as diabetes, kidney disease, and obesity that add their own inflammatory burden. All of these forces push NPAR upward, which is likely why NPAR captures so much prognostic information in that population.

For a general wellness population, the NPAR story reinforces rather than complicates the case for monitoring inflammation over time. The clinical research showing that nutritional depletion and immune overactivation combine in a particularly dangerous way is a reminder that inflammation is not a single lever. Sleep, diet quality, protein intake, physical activity, and stress management all influence different facets of the inflammatory state. CRP gives you a read on one well-validated facet. Tracking it over weeks and months, and looking at the direction of the trend as you make lifestyle changes, puts a useful number on a process that would otherwise be invisible.

What This Research Means in Practice

For clinicians caring for heart failure patients, the NPAR data add a practical option. Both neutrophil percentage and albumin are already ordered on virtually every heart failure hospitalization. Calculating NPAR requires no additional test, no additional cost, and no new laboratory infrastructure. A high NPAR at admission could flag patients who need more intensive monitoring, earlier nutritional support, or closer follow-up after discharge. The September 2026 study's authors specifically called for further investigation into NPAR as a tool for individualized risk assessment in acute heart failure care.

For researchers, the NPAR findings underscore the continued productivity of studying inflammation in cardiovascular disease. Despite decades of research into CRP, IL-6, and other cytokines, combinations of standard laboratory values are still revealing new predictive information. The inflammation-malnutrition axis captured by NPAR is not new biology, but extracting it from routine labs in a way that adds incremental prognostic value over established markers is a real advance.

For individuals tracking their own wellness, the key message is that different inflammation markers measure different things, and that CRP remains a meaningful general-purpose window into systemic inflammatory activity. Persistent elevation is worth discussing with a healthcare provider, who may order additional markers or evaluate for underlying causes. Tracking trends over time alongside diet, sleep, and exercise changes gives you data that can inform those conversations. Sensa is designed as a general wellness tool for that kind of longitudinal monitoring, not as a substitute for clinical care or a diagnostic instrument.

Sources

• Chen Z, Wei Y, Wang Y, et al. Neutrophil-Percentage-to-Albumin Ratio Outperforms High-Sensitivity C-Reactive Protein in Predicting Mortality in Acute Heart Failure: Evidence from a Nationwide Prospective Cohort. Journal of Inflammation Research, 2026. doi.org/10.2147/JIR.S605643 (PMID: 42708065)
• Patel D, Acharya S, Patel S, et al. Association of the Neutrophil Percentage-to-Albumin Ratio with All-Cause Mortality in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Cardiology in Review, 2026. doi.org/10.1097/CRD.0000000000001398 (PMID: 42426924)
• Aktaş I, Yaşar E. Neutrophil Percentage-to-Albumin Ratio as a Novel Biomarker in Patients with Group 1 Pulmonary Arterial Hypertension. Nigerian Journal of Clinical Practice, 2026. doi.org/10.4103/njcp.njcp_816_25 (PMID: 42241205)
• Mavroudis A, Fragoulis C, Mavromoustakou K, et al. Mechanisms of Cardiac Inflammation in Heart Failure: Role of Dietary Patterns, Nutrients, and Therapeutic Strategies. Nutrients, 2026. doi.org/10.3390/nu18061005 (PMID: 41901180)

Frequently Asked Questions

What is NPAR and how is it different from CRP?

NPAR stands for neutrophil-percentage-to-albumin ratio. It is calculated by dividing the proportion of white blood cells that are neutrophils by the serum albumin level, both of which come from standard routine blood tests. CRP reflects how strongly the liver is producing acute-phase proteins in response to cytokine signaling. NPAR captures a related but distinct picture: the activity of the innate immune system combined with the body's nutritional and protein-storage status. In patients with acute heart failure, NPAR appears to carry slightly more prognostic information than hs-CRP, likely because it encodes both inflammatory activity and malnutrition simultaneously.

Does the new NPAR study mean CRP is no longer useful?

No. The study was conducted specifically in hospitalized patients with acute heart failure, a population with very high and fluctuating inflammatory burden. In that narrow setting, NPAR provided incremental value over hs-CRP. CRP has decades of research behind it across healthy and general populations and remains the standard tool for assessing chronic low-grade inflammation in everyday life. The two markers are complementary rather than competing.

What did the September 2026 study find about NPAR and heart failure mortality?

The study followed 4,622 patients with acute heart failure for a median of nearly five years. Patients in the highest NPAR quartile had a hazard ratio of 1.74 for all-cause mortality and 1.72 for cardiovascular mortality compared with those in the lowest quartile. Adding NPAR to standard clinical prediction models improved mortality discrimination and correctly reclassified roughly one in ten patients. When directly compared, NPAR outperformed hs-CRP, and combining both markers did not add further benefit beyond NPAR alone.

What can I do to keep my own inflammation in check?

The research on cardiac inflammation consistently points to the same set of lifestyle factors: a diet high in vegetables, legumes, whole grains, and fish while low in ultra-processed foods and added sugar; regular physical activity; adequate sleep; and stress management. A Mediterranean-style dietary pattern has been shown to reduce circulating CRP and IL-6. Tracking your CRP over time with an at-home wellness test can help you see whether lifestyle changes are moving your numbers in the right direction, but any persistent elevation is worth discussing with a healthcare provider.